应用聚合酶链反应技术诊断男性性传播疾病156例报告

应用聚合酶链反应技术（ＰＣＲ）对１５６例男性性传播疾病进行检测，检出单纯急性淋菌性尿道炎（ＡＧＵ）５９例（３７．８％），单纯非淋菌性尿道炎（ＮＧＵ）４８例（３０．８％）ＡＧＵ合并ＮＧＵ４９例（３１．４％），认为，对性传播尿道炎必须根据临床症状和ＰＣＲ的检测阳性结果作全面彻底治疗，方能取得良好的效果。     

0.02%络合碘膀胱尿道灌注治疗顽固性淋菌性尿道炎65例报告

０．０２％络合碘膀胱尿道灌注治疗顽固性淋菌性尿道炎６５例报告湖北三峡学院医学院附院男性学研究室（宜昌４４３００３）聂勇郭贤坤文春森我院从１９９３年６月～１９９６年１２月采用０．０２％络合碘溶液行膀胱尿道灌注治疗顽固性淋菌性尿道炎患者６５例（治疗组），...     

药物热盐水尿道张力灌注治疗慢性淋菌性尿道炎

急性淋菌性尿道炎不经治疗或治疗不当，淋病奈瑟菌在一定条件下能长期繁殖生长，成为慢性淋菌性尿道炎。慢性淋菌性尿道炎在治疗上较棘手，我院应用聚合酶链反应（PCR）技术确诊并施行热盐水尿道张力灌注治疗32例，取得了满意疗效。现报告如下。     

PCR检测衣原体及支原体感染的临床意义

应用聚合酶链反应（ＰＣＲ）对１２８例疑为淋菌性或非淋菌性尿道炎患者进行沙眼衣原体和解脲支原体检测，结果获得阳性者５３例，衣原体阳性者３３例，占６２．３％，支原体阳性者２８例，占５２．８％，其中衣原体和支原体均阳性者８例，占１５．１％。并就ＰＣＲ检测的诊断价值及临床意义进行了讨论。认为积极开展ＰＣＲ技术对衣原体和支原体进行检测，是提高非淋菌性尿道炎诊断率及治愈率的重要措施。     

重复感染淋菌性尿道炎286例临床分析

重复感染淋菌性尿道炎２８６例临床分析福建省龙岩地区第一医院泌尿外科（龙岩３６４０００）张永良检验科戴庆福淋病是通过性传播的一种特异性感染性疾病。人类为淋菌的唯一宿主。重复感染的淋菌性尿道炎，临床表现及其治疗均较初发者复杂。我科３年来共收治淋菌性尿道炎...     

头孢三嗪治疗急性淋菌性尿道炎的体会

应用头孢三嗪治疗急性淋菌性尿道炎中 ,有完整资料者 16 3例 ,临床治疗中体会到头孢三嗪的用药剂量 ,用药方式及与其他抗菌素合并使用等对疗效有较大影响。1.　一般资料1.1　急性淋菌性尿道炎的诊断标准1.1.1　典型的不洁性交史 ,潜伏期 3～ 12天。1.1.2　发病期均有典型的尿痛及尿道脓性分泌物。1.1.3　尿道分泌物涂片 ,经革兰氏染色 ,在白细胞内外均发现有革兰氏阴性双球菌 (Ｇ )。1.2　用药方式1.2 .1　单剂量头孢三嗪 ,2 50ｍｇ ,1次性肌注 (ｉｍ)。1.2 .2　单剂量头孢三嗪 1ｇ ,1次性静脉推注 (ｉｖ)。1.2 .3　单剂量头孢三嗪 1ｇ ,静…     

中西医结合治疗慢性淋菌性前列腺炎68例

中西医结合治疗慢性淋菌性前列腺炎６８例湖南省中医学院附属二院皮肤科（长沙４１０００５）刘汉长，王明忠慢性淋菌性前列腺炎（Ｃｈｒｏｎｉｃｇｏｎｏｒｒ－ｈｏｅａｌｐｒｏｓｔａｔｉｔｉｓ，ＣＧＰ）是男性淋菌性前尿道炎未彻底治疗，炎症蔓延至后尿道所致。本文采...     

PCR用于性传播尿道炎宫颈炎的诊断及疗效监测

为探讨性传播尿道炎、宫颈炎的诊断及疗效监测方法，采用聚合酶链反应（ＰＣＲ）对３０例慢性性传播尿道炎、宫颈炎患者进行病原体检查，同时对２０例急性淋菌性尿道炎、宫颈炎患者进行疗效监测。结果３０例慢性性传播尿道炎、宫颈炎的确诊率达９０％，２０例急性淋菌性尿道炎、宫颈炎复查治愈率达９５％。认为该方法不仅具有极高的诊断价值，而且也是一种有效的疗效监测手段，敏感性强，特异性好，快速准确值得推广。     

淋菌性前列腺炎64例报告

淋菌性前列腺炎６４例报告浙江乐清市人民医院（３２５６００）方佛安，林建新在急性淋球菌感染中，尿道炎若未经及时和合理治疗，淋球菌必将侵人前列腺而形成难治的前列腺炎。我院自１９８７年４月～１９９２年４月共治疗淋菌性前列腺炎６４例，现报道如下：临床资料１．...     

PCR检测衣原体及其在男性尿道感染中的意义

应用聚酶链反应（ＰＣＲ）检测６０４例临床已确诊的男性泌尿系感染患者沙眼衣原体（ＣＴ）感染情况，发现ＣＴ阳性率为：急性淋菌性尿道炎（ＡＧＵ）占２６．９％（１１７／４３５），淋菌感染后尿道炎（ＰＧＵ）占４８．５％（３２／６６），非淋菌性尿道炎（ＮＧＵ）占３１．１％（３２／１０３）。认为ＰＣＲ技术是临床快速诊断男性ＣＴ尿道炎的有效方法。     

Clinical studies of Chlamydia trachomatis in male urethritis

From January through December 1986, the urethral smear specimens from 132 male urethritis patients were examined by using Chlamydia trachomatis direct specimen test (Micro Trak). C. trachomatis was detected in 59 (44.7%) out of 132 male urethritis patients, 8 (30.8%) out of 26 patients with gonococcal urethritis (GU), and 51 (48.1%) out of 106 patients with non-gonococcal urethritis (NGU). In 5 (31.3%) out of 16 cases, already treated in other hospitals, infection of C. trachomatis was revealed. The age distribution of the patients with chlamydial urethritis (NGU-C) was between 19 and 52 years old, and the average was 30.9 years old. The peak incubation periods of GU and NGU-C were seen within 7 days and between 8 and 14 days, respectively. In NGU-C patients, 70.6% of them showed WBC less than or equal to 9/hpf in first voided urine sediment. The source of infection was a non-prostitute in 22.2% and a prostitute in 72.2% of GU, while in NGU-C 23.5% was infected from a non-prostitute, and 62.7% from a prostitute. Ofloxacin (OFLX) was administered in a daily dosage of 600 mg (in 3 divided oral doses) for 5 to 14 days in 38 NGU-C patients, and C. trachomatis was eliminated in all cases after the treatment.     

Clinical study of male urethritis in Oogaki Municipal Hospital

We studied 181 patients diagnosed with male urethritis at Oogaki Municipal Hospital from April 2002 to March 2004. Twenty-two out of 92 patients diagnosed with gonococcal urethritis (GU) and 52 out of 89 patients diagnosed with non-gonococcal urethritis (NGU) were positive for Chlamidia trichomatis by polymerase chain reaction (PCR). Most patients of male urethritis were in their twenties. Of GU patients, 39 (67%) were infected from commercial sex workers (CSWs). Of NGU patients, 12 (30%) were infected from CSWs, 24 (40%) from girl friends and 4 (10%) from their Twenty-eight (48%) out of GU patients were infected through oral sex. spouse. Eighty-three GU patients were treated with SPCM (2 g, one shot). Fifty-five patients could be evaluated for the efficacy of treatment. Elimination rate of Neisseria gonorrhoeae was 100% and 14 out of 18 patients with persisting urethritis had C. trichomatis. Eighty-two NGU patients were treated with minocycline, tosufloxacin, levofloxacin, gatiflixacin or clarithromycine. Sixty-six patients could be evaluated for the efficacy of treatment. Forty-one patients were diagnosed with non-gonococcal chlamydial urethritis (NGCU) and 25 patients were diagnosed with non-gonococcal, non-chlamydial urethritis (NGNCU). The clinical curative rate of NGCU and NGNCU was 93% (38/41) and 80% (20/25), respectively.     

Azithromycin treatment for nongonococcal urethritis negative for Chlamydia trachomatis,Mycoplasma genitalium,Mycoplasma hominis,Ureaplasma parvum,and Ureaplasma urealyticum

Some patients with nongonococcal urethritis (NGU) are negative for Chlamydia trachomatis, mycoplasmas, and ureaplasmas. The optimal antimicrobial chemotherapy for such NGU has not fully been clarified. We assessed the efficacy of azithromycin for treatment of nonmycoplasmal, nonureaplasmal, nonchlamydial NGU (NMNUNCNGU). Thirty‐eight men whose first‐pass urine was negative for Chlamydia trachomatis, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum, and Ureaplasma urealyticum were treated with a single dose of 1 g azithromycin. Urethritis symptoms and polymorphonuclear leukocytes in urethral smears or in first‐pass urine were assessed before and after treatment with azithromycin. Thirty‐two (84.2%) of the 38 men with NMNUNCNGU showed no signs of urethral inflammation after treatment. The efficacy of this azithromycin regimen was comparable to that of the 7‐day regimen of levofloxacin, gatifloxacin, minocycline, or clarithromycin reported previously. A single dose of 1 g azithromycin, which is effective not only for NGU due to specific pathogens but also for NMNUNCNGU, is an appropriate treatment for NGU.     

Treatment of nongonococcal urethritis--studies on clinical effects of ofloxacin

Clinical effects of ofloxacin (OFLX) in the treatment of chlamydial urethritis was compared with those in the treatment of non-chlamydial urethritis. Chlamydia trachomatis was isolated from 33 (39.3%) out of 84 patients with nongonococcal urethritis. OFLX was administered at a dose of 100 mg, three times daily (300 mg) for 14 days. In 31 (93.3%) of the 33 patients with chlamydial urethritis, C. trachomatis was eliminated within 7 to 14 days after the start of administration, and, in two patients, inclusion bodies decreased in number but persisted. The subjective and objective clinical symptoms, urethral discharge, polymorphonuclear leucocyte (PMNL) in smears, and pyuria in VB1 of the patients with chlamydial urethritis, disappeared in 56.0, 57.6, and 63.0% of the cases, and improved in 24.0, 30.0 and 29.6% respectively, whereas those of the patients with non-chlamydial urethritis, urethral discharge, PMNL, and pyuria in VB1 disappeared in 57.6, 56.9 and 32.9%, and improved in 26.9, 13.7 and 37.9%, respectively. There was no significant difference in the clinical effects of OFLX between cases of chlamydial urethritis and those of non-chlamydial urethritis. Marked improvement in clinical symptoms were observed between day 7 and day 14 of medication in cases of both chlamydial and non-chlamydial urethritis. In nine out of 11 cases of non-chlamydial urethritis where OFLX was ineffective, no Ureaplasma nor aerobes, nor C. trachomatis, were isolated. In the remaining two cases where Ureaplasma and S. epidermidis were isolated respectively, these two bacteria were eradicated after medication, but urethral discharge and PMNL remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)     

Ureaplasma urealyticum and mycoplasma hominis in male urethritis]

We conducted a multi-center clinical study to evaluate the role of Ureaplasma urealyticum and Mycoplasma hominis in male urethritis. The incidence of each organism in first-voided urine samples of 160 male urethritis patients, including 28 with gonococcal and 126 with non-gonococcal urethritis, was investigated. U. urealyticum and M. hominis were isolated from 13.6% and 6.5%, respectively, of the urine samples, and the concentration of each mycoplasma exceeded 10(3) ccu/ml (color changing units/ml) in 5.2% and 3.9%, respectively. Among 64 patients with non-gonococcal non-chlamydial urethritis, U. urealyticum and M. hominis concentration exceeding more than 10(3) ccu/ml were detected in only two and one samples, respectively. The incidence among urethritis patients with a concentration of either mycoplasma exceeding 10(3) ccu/ml was not significantly greater than that among subfertile males without urethritis. The findings of the present study suggest that, although mycoplasmas may cause urethritis in some patients, the incidence of urethritis due to U. urealyticum or M. hominis is low among patients with non-gonococcal, non-chlamydial urethritis.     

Treatment of chlamydial urethritis--studies on clinical effects of ofloxacin

Clinical effects of ofloxacin (OFLX) in the treatment of the patients with chlamydial urethritis was studied. OFLX was administered at a dose of 200 mg, three times daily (600 mg) for 14 days. In all of the 26 patients with chlamydial urethritis, C. trachomatis was eliminated in 7 to 14 days after the start of administration. The subjective clinical symptoms such as pain on urination and abnormal urethral feeling was disappeared in all cases within 7 days after the administration. The objective clinical symptoms, urethral discharge, polymorphonuclear leukocyte (PMNL) in urethral discharge and PMNL in first urine were improved in 94, 68, 91% respectively on 14 days after the administration. Overall clinical efficacy rate of OFLX on 7 days, 14 days and 21 days after the administration in this study was 63, 82, 91% respectively. Whereas subjective symptoms of side effects were noted in 2 patients (7.6%), any additional medical care was needed in none of them. Because of the marked improvement of clinical symptoms and the safety administration, OFLX could be the first regimen to be chosen for the treatment of the patients with chlamydial urethritis.     

Clinical studies of male urethritis caused by Chlamydia trachomatis

From January through June 1983, 178 male patients with urethritis were investigated on the etiology and epidemiological and clinical features. By using Chlamydia trachomatis direct specimen test (Micro Trak), C. trachomatis was detected in 60 (47.2%) among 127 patients with non-gonococcal urethritis, while it was detected 8 (15.7%) among 51 patients with gonococcal urethritis. The source of infection was a non-prostitute in 30% of chlamydial urethritis, while in gonorrheal urethritis only one patient was infected from a non-prostitute. Mean incubation period of chlamydial and gonorrheal urethritis was 28.5 and 9.2 days, respectively. In chlamydial urethritis, 33.3% of patients did not complain of urination pain and 20.4% showed no urethral discharge. Symptoms of chlamydial urethritis were milder than those of gonorrheal urethritis.     

Diagnosis of gonococcal urethritis and chlamydial urethritis by polymerase chain reaction]

A polymerase chain reaction (PCR) method was compared to standard methods (cultures for Neisseria gonorrhoeae and Chlamydia trachomatis and an enzyme-immunoassay for C. trachomatis) in diagnosis of gonococcal and chlamydial urethritis in 40 male patients with urethritis. Gonococcal urethritis was diagnosed by detection of a 206 bp DNA fragment amplified by PCR with N. gonorrhoeae-specific primers. Chlamydial urethritis was diagnosed by detection of a 242 bp DNA fragment amplified by PCR with C. trachomatis-specific primers. Gonococcal and chlamydial urethritis, gonococcal and non-chlamydial urethritis, non-gonococcal and chlamydial urethritis, and non-gonococcal and non-chlamydial urethritis were diagnosed in 8, 10, 14 and 8 patients, respectively, by the PCR method. In 9 patients with gonococcal and chlamydial urethritis, 10 with gonococcal and non-chlamydial urethritis, 12 with non-gonococcal and chlamydial urethritis, and 9 with non-gonococcal and non-chlamydial urethritis, diagnosed by the standard methods, the coincidence rates of the PCR to the standard methods were 78% (7/9), 90% (9/10), 100% (12/12), and 89% (8/9), respectively. The overall coincidence rate between the PCR and the standard methods in diagnosis of urethritis were high (90%). In addition, N.gonorrhoeae and C.trachomatis could be simultaneously detected from one urethral sample in approximately 6 hours by means of the PCR. Thus, the PCR method could clinically be applied and would offer several advantages to diagnosis of urethritis, compared to the standard methods.     

GPH基因技术在治疗非淋等泌尿生殖感染中的应用

目的：探讨GPH基因技术在治疗非淋等泌尿生殖感染中的临床效果。方法选择2012年8月~2013年10月哈尔滨市223例性病就诊者进行治疗,其中非淋菌性尿道炎91例,淋病64例,尖锐湿疣38列,生殖器疱疹,24例,软下疳6例,均有非婚性接触史。结果经过长达4～6个月的跟踪随访,治愈率为98.21%。结论GPH基因技术在治疗非淋等泌尿生殖感染方面取得了显著效果,充分显示出GPH基因技术所具有的疗效显著、治疗安全、不易复发的突出优势。     

Clinical effectiveness of short-term administration of norfloxacin in acute urethritis

Thirty patients with acute urethritis were treated with short-term administration of norfloxacin. The drug was administered randomly in two regimens: Two 400 mg oral doses for a single day or three 200 mg oral doses for three days. For gonorrheal urethritis, the efficacy rates of one and three-day administrations were 75 and 90%, respectively. For non-gonorrheal urethritis, they were 75% each. No adverse effects were observed. The results indicate that short-term administration of norfloxacin is useful in the treatment of acute urethritis, especially for gonorrheal urethritis.